<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20161022030424N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-06-07</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>5:2 intermittent fasting diet with high protein content in knee osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>To investigate the effect of a 5:2 intermittent fasting diet with high protein content versus daily calorie restriction balanced diet on anthropometric indices, body composition analysis, functional status, pain intensity, and serum markers of inflammation and oxidative stress in overweight and obese postmenopausal women with knee osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/84099</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: We will use a stratified block randomization method for allocation. The computer-generated code, created using SAS software version 8.01, will be used to create a randomized sequence by a statistician outside the project's research team. Randomization will be stratified based on body mass index and osteoarthritis severity (mild, moderate, and severe). Serially numbered, opaque, sealed packets will be used to ensure allocation, Blinding description: Blinding the patients is not feasible in this trial. A trained nutritionist will ban diet-related conversations between assessors and patients during the study. Outcome assessors and the person responsible for statistical analysis will be blinded to the type of interventions received until the end of the study.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 5:2 fasting diet with high-protein intermittent content for 4 months (This diet involves maintaining normal eating habits for five consecutive days a week, maintaining an energy intake range of 1,400 to 1,600 kcal/day for women. On the remaining two days, a light fasting diet is adopted, limiting daily energy intake to 600 kcal/day. The percentage of protein in daily calories consumed is designed to be 2 grams per kilogram of body weight on all days of the week.). Intervention 2: Control group: Balanced low-calorie diet (500 kcal is deducted from the average 3-day energy intake of the individual, and the diet will be designed with the following distribution: fat less than 30% of calories, carbohydrates 55-60% of calories, and protein 10-15% of calories).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Neda Dolatkhah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza Educational and Medical Center, opposite the Central Organization of the University, Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 41 3334 7054</telephone>
        <email>neda_dolatkhah@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Neda dolatkhah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza Educational and Medical Center, opposite the Central Organization of the University, Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 41 3334 7054</telephone>
        <email>neda_dolatkhah@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of knee osteoarthritis by a physical medicine specialist
Stopping menstrual cycle naturally 12 months ago
Body mass index of 25 kg/m2 and above
Not having another inflammatory disease such as rheumatoid arthritis
No intra-articular injection for the past 3 months
No oral medication (nonsteroidal anti-inflammatory drugs) for one week prior to study entry.</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>70 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Daily calorie intake of less than 800 and more than 4200 kcal
A deviation from a specific eating pattern due to medical or other reasons
Use of dietary supplements, diuretics, or laxatives during the intervention period
Participation in sports programs or changes in physical activity
Failure to follow the recommended diet
Use of weight-affecting medications</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary gonarthrosis, bilateral</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 5:2 fasting diet with high-protein intermittent content for 4 months (This diet involves maintaining normal eating habits for five consecutive days a week, maintaining an energy intake range of 1,400 to 1,600 kcal/day for women. On the remaining two days, a light fasting diet is adopted, limiting daily energy intake to 600 kcal/day. The percentage of protein in daily calories consumed is designed to be 2 grams per kilogram of body weight on all days of the week.)</i_keyword>
      <i_keyword>Control group: Balanced low-calorie diet (500 kcal is deducted from the average 3-day energy intake of the individual, and the diet will be designed with the following distribution: fat less than 30% of calories, carbohydrates 55-60% of calories, and protein 10-15% of calories)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight. Timepoint: Weight measurement at the beginning of the study (before the start of the intervention) and 1, 2, 3 and 4 months after the start of the intervention. Method of measurement: Seca digital scale.</prim_outcome>
      <prim_outcome>Body mass index. Timepoint: Body mass index measurement at the beginning of the study (before the start of the intervention) and 1, 2, 3 and 4 months after the start of the intervention. Method of measurement: Calculation.</prim_outcome>
      <prim_outcome>Body fat mass. Timepoint: Measurement of body fat mass at the beginning of the study (before the start of the intervention) and 4 months after the start of the intervention. Method of measurement: Body analyzer.</prim_outcome>
      <prim_outcome>Fat-free body mass. Timepoint: Measurement of fat-free body mass at the beginning of the study (before the start of the intervention) and 4 months after the start of the intervention. Method of measurement: Body analyzer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain intensity. Timepoint: Pain intensity measurement at the beginning of the study (before the start of the intervention) and 4 months after the start of the intervention. Method of measurement: Visual Analogue Scale.</sec_outcome>
      <sec_outcome>Functional status. Timepoint: Measurement of functional status at the beginning of the study (before the start of the intervention) and 4 months after the start of the intervention. Method of measurement: Western Ontario and McMaster Universities Arthritis Index (WOMAC).</sec_outcome>
      <sec_outcome>High-sensitivity C-reactive protein (hsCRP) level. Timepoint: Measurement of high-sensitivity C-reactive protein (hsCRP) levels at the beginning of the study (before the start of the intervention) and 4 months after the start of the intervention. Method of measurement: Biochemical analysis.</sec_outcome>
      <sec_outcome>Total antioxidant capacity (TAC) level. Timepoint: Measurement of total antioxidant capacity (TAC) levels at the beginning of the study (before the start of the intervention) and 4 months after the start of the intervention. Method of measurement: Biochemical analysis.</sec_outcome>
      <sec_outcome>Malondialdehyde (MDA) level. Timepoint: Measurement of Malondialdehyde (MDA) levels at the beginning of the study (before the start of the intervention) and 4 months after the start of the intervention. Method of measurement: Biochemical analysis.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-02-15</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for Research and Technology, Central Building No. 2, Third Floor, Tabriz University of Medical Sciences, Golgasht Street Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
